+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Systemic Mastocytosis Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 185 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6106949
The global market for Systemic Mastocytosis Treatment was estimated at US$530.9 Million in 2024 and is projected to reach US$709.1 Million by 2030, growing at a CAGR of 4.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Systemic Mastocytosis Treatment market.

Global Systemic Mastocytosis Treatment Market - Key Trends & Drivers Summarized

Why Is Systemic Mastocytosis Gaining Attention in Precision Medicine?

Systemic mastocytosis (SM) is a rare, hematologic neoplasm characterized by abnormal accumulation of mast cells in various organs such as the skin, bone marrow, liver, and spleen. The disease ranges from indolent forms to aggressive subtypes, with symptoms caused by both organ infiltration and mast cell mediator release (e.g., histamine, tryptase). The complex clinical presentation, often involving anaphylaxis, gastrointestinal dysfunction, and bone pain, makes early diagnosis and personalized treatment essential. Advances in molecular diagnostics-particularly the identification of KIT D816V mutations-have allowed for more accurate disease classification and prognosis. As a result, SM is now at the forefront of targeted therapy development in rare oncology, with a growing number of tailored treatment options being explored and approved.

How Are Targeted Therapies Changing the Systemic Mastocytosis Treatment Landscape?

The introduction of tyrosine kinase inhibitors (TKIs) targeting the KIT mutation has redefined treatment strategies. Avapritinib, a selective inhibitor approved for advanced SM, has shown significant clinical benefit in terms of symptom relief and disease burden reduction. Midostaurin, another KIT-targeted therapy, remains a key treatment for aggressive and advanced forms. Combination therapies and novel agents-such as anti-IgE antibodies and mast cell stabilizers-are being evaluated for managing mediator-related symptoms and co-existing allergic conditions. Additionally, research into immunomodulatory drugs and newer kinase inhibitors is ongoing to address drug-resistant or smoldering SM variants. Personalized dosing strategies, based on mutation load and disease subtype, are further improving therapeutic outcomes and tolerability.

Where Is Treatment Access and Disease Monitoring Improving for SM Patients?

Specialized hematology and rare disease centers are implementing comprehensive SM care programs that combine genomic testing, multidisciplinary care, and longitudinal patient monitoring. Disease-specific scoring tools are being integrated into EHRs to guide therapy selection and track progression. Patient advocacy networks are collaborating with pharmaceutical companies to facilitate compassionate use and expanded access to investigational therapies. Digital platforms are supporting remote symptom tracking and treatment response, especially in countries with limited access to specialists. Increasing awareness among allergists, dermatologists, and oncologists is helping reduce diagnostic latency, a key barrier to timely intervention. The establishment of global SM registries is also improving clinical insight and informing policy development.

The Growth in the Systemic Mastocytosis Treatment Market Is Driven by Several Factors

It is driven by the availability of mutation-specific targeted therapies, advances in molecular diagnostics, and the expansion of rare disease treatment infrastructure. The approval and commercialization of KIT-targeting TKIs have opened a new therapeutic era for patients with advanced SM. Growing inclusion of SM in rare cancer reimbursement programs and orphan drug pipelines is improving treatment accessibility. Development of companion diagnostics and biomarker-guided monitoring tools is enhancing treatment precision and patient outcomes. Increased research funding, international clinical collaborations, and heightened physician awareness are collectively sustaining momentum in the systemic mastocytosis treatment landscape.

Scope Of Study:

The report analyzes the Systemic Mastocytosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Type (AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment, Other Treatments); Administration Route (Oral Administration, Injectable Administration, Topical Administration)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the AK-002 Treatment segment, which is expected to reach US$305.2 Million by 2030 with a CAGR of a 4.4%. The BLU-285 Treatment segment is also set to grow at 5.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $139.6 Million in 2024, and China, forecasted to grow at an impressive 4.9% CAGR to reach $114.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Systemic Mastocytosis Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Systemic Mastocytosis Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Systemic Mastocytosis Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AB Science SA, AbbVie Inc., Allakos Inc., AstraZeneca, Bayer AG and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Systemic Mastocytosis Treatment market report include:

  • AB Science SA
  • AbbVie Inc.
  • Allakos Inc.
  • AstraZeneca
  • Bayer AG
  • Blueprint Medicines Corp.
  • Bristol-Myers Squibb Company
  • Cogent Biosciences Inc.
  • Deciphera Pharmaceuticals
  • Eli Lilly & Company
  • Glenmark Pharmaceuticals Ltd.
  • Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Mylan NV (now Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Aventis
  • Teva Pharmaceutical Industries Ltd.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Systemic Mastocytosis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Improved Diagnostic Rates and Classification Guidelines Drive Growth in Systemic Mastocytosis Treatment
  • Advancements in KIT Mutation Inhibitors Expand Therapeutic Possibilities for Advanced SM Subtypes
  • Rising Awareness Among Hematologists and Oncologists Fuels Earlier Treatment Initiation
  • Growth in Targeted Therapy Approvals Accelerates Market Entry of Novel Small Molecules
  • Expansion of Symptom Management Strategies Supports Broader Patient Coverage
  • Development of Non-Cytotoxic Therapies Improves Long-Term Tolerability and Outcomes
  • Emergence of Biomarker-Based Patient Stratification Strengthens Role of Personalized Medicine
  • Increased Enrollment in Clinical Trials Enhances Global Accessibility to Emerging Treatments
  • Improved Risk Classification Systems Facilitate Proactive Treatment for High-Risk Patients
  • Integration of Digital Tools for Symptom Tracking Supports Real-Time Disease Management
  • Demand for Oral Formulations With Lower Systemic Toxicity Drives Market Shift
  • Increased Awareness of Misdiagnosis and Underreporting Promotes Uptake of Confirmatory Testing
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Systemic Mastocytosis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Systemic Mastocytosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Systemic Mastocytosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for AK-002 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for AK-002 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for AK-002 Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for BLU-285 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for BLU-285 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for BLU-285 Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Brentuximab Vedotin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Brentuximab Vedotin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Brentuximab Vedotin Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Crenolanib Besylate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Crenolanib Besylate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Crenolanib Besylate Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
JAPAN
  • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
CHINA
  • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: China 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
EUROPE
  • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Systemic Mastocytosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
FRANCE
  • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: France 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
GERMANY
  • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
UNITED KINGDOM
  • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
REST OF EUROPE
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Rest of Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Rest of Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
ASIA-PACIFIC
  • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Asia-Pacific 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Asia-Pacific 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
REST OF WORLD
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of World 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of World Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Rest of World 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AB Science SA
  • AbbVie Inc.
  • Allakos Inc.
  • AstraZeneca
  • Bayer AG
  • Blueprint Medicines Corp.
  • Bristol-Myers Squibb Company
  • Cogent Biosciences Inc.
  • Deciphera Pharmaceuticals
  • Eli Lilly & Company
  • Glenmark Pharmaceuticals Ltd.
  • Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Mylan NV (now Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Aventis
  • Teva Pharmaceutical Industries Ltd.

Table Information